{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:29:19Z","timestamp":1648650559729},"reference-count":36,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The immune response against the infecting group A streptococcus (GAS) extracellular products (EP) was determined in acute- and convalescent-phase sera from 75 patients with different clinical manifestations of GAS infection. All EP elicited a high proliferative response in human peripheral blood mononuclear cells. In patients with bacteremia, low neutralization in acute-phase sera was associated with development of streptococcal toxic shock syndrome. Lack of neutralization in acute-phase sera was more common in patients infected with the T1\n            <jats:italic>emm1<\/jats:italic>\n            serotype. The majority of patients did not develop the ability to neutralize the mitogenic activity of their infecting isolate despite a significant increase in enzyme-linked immunosorbent assay titer in early convalescent-phase sera. In patients with the ability to neutralize GAS EP, the immune response remained high over at least 3 years. In contrast, the neutralization capacity conferred by intravenous immunoglobulin and\/or plasma treatment disappeared within 3 months.\n          <\/jats:p>","DOI":"10.1128\/cvi.00271-06","type":"journal-article","created":{"date-parts":[[2006,11,9]],"date-time":"2006-11-09T01:41:02Z","timestamp":1163036462000},"page":"44-51","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Dynamics of the Immune Response against Extracellular Products of Group A Streptococci during Infection"],"prefix":"10.1128","volume":"14","author":[{"given":"Linda","family":"Maripuu","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjo\u0308rn","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlis","family":"Pauksen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Norgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Biomedical Laboratory Science, Umea\u030a University, Umea\u030a, Sweden"},{"name":"Division of Infectious Diseases, Institution of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Infectious Disease, Akademiska Hospital, Uppsala, Sweden"},{"name":"Department of Clinical Microbiology, Clinical Bacteriology, Umea\u030a University, Umea\u030a, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1074\/jbc.271.2.1081","volume":"271","year":"1996","unstructured":"Akesson, P., A. G. Sjoholm, and L. Bjorck. 1996. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J. Biol. Chem.271:1081-1088.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.imlet.2003.11.003","volume":"91","year":"2004","unstructured":"Arad, G., D. Hillman, R. Levy, and R. Kaempfer. 2004. Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol. Lett.91:141-145.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/74672","volume":"6","year":"2000","unstructured":"Arad, G., R. Levy, D. Hillman, and E. Kaempeer. 2000. Superantigen antagonist protects against lethal shock and defines new domain of T-cell activation. Nat. Med.6:414-421.","journal-title":"Nat. Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.4.1871-1877.1999"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1473-3099(03)00576-0","volume":"3","year":"2003","unstructured":"Bisno, A. L., M. O. Brito, and C. M. Collins. 2003. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis.3:191-200.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.3.793-799.1993"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.6.3523-3534.2000"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","volume":"37","year":"2003","unstructured":"Darenberg, J., N. Ihendyane, J. Sjolin, E. Aufwerber, S. Haidl, P. Follin, J. Andersson, A. Norrby-Teglund, and the StreptIg Study Group. 2003. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis.37:333-340.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1056\/NEJM199608223350803","volume":"335","year":"1996","unstructured":"Davies, H. D., A. McGeer, B. Schwartz, K. Green, D. Cann, A. E. Simor, and D. E. Low for The Ontario Group A Streptococcal Study Group. 1996. Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med.335:547-554.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/45.suppl_1.3","volume":"45","year":"2000","unstructured":"Efstratiou, A. 2000. Group A streptococci in the 1990s. J. Antimicrob. Chemother.45(Suppl.):3-12.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3101-3109.2005"},{"key":"e_1_3_2_13_2","first-page":"1350","volume":"43","year":"1999","unstructured":"Eriksson, B. K. G., J. Andersson, S. E. Holm, and M. Norgren. 1999. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk for the streptococcal toxic shock syndrome. J. Infect. Dis.43:1350-1357.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/379013","volume":"37","year":"2003","unstructured":"Eriksson, B. K. G., M. Norgren, K. McGregor, B. G. Spratt, and B. H. Normark. 2003. Group A streptococcal infections in Sweden: a comparative study of invasive and noninvasive infections and analysis of dominant T28 emm28 isolates. Clin. Infect. Dis.37:1189-1193.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"16561","DOI":"10.1074\/jbc.M301995200","volume":"278","year":"2003","unstructured":"Frick, I. M., P. Akesson, M. Rasmussen, A. Schmidtchen, and L. Bjorck. 2003. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J. Biol. Chem.278:16561-16566.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(04)00057-1","volume":"116","year":"2004","unstructured":"Herwald, H., H. Cramer, M. Morgelin, W. Russell, U. Sollenberg, A. Norrby-Teglund, H. Flodgaard, L. Lindbom, and L. Bjorck. 2004. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell116:367-379.","journal-title":"Cell"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1073\/pnas.112039899","volume":"99","year":"2002","unstructured":"Hoe, N. P., R. M. Ireland, F. R. DeLeo, B. B. Gowen, D. W. Dorward, J. M. Voyich, M. Liu, E. H. Burns, Jr., D. M. Culnan, A. Bretscher, and J. M. Musser. 2002. Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc. Natl. Acad. Sci. USA99:7646-7651.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/infdis\/166.1.31","volume":"166","year":"1992","unstructured":"Holm, S. E., A. Norrby, A. M. Bergholm, and M. Norgren. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J. Infect. Dis.166:31-37.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","volume":"28","year":"1999","unstructured":"Kaul, R., A. McGeer, A. Norrby-Teglund, M. Kotb, B. Schwartz, K. O'Rourke, J. Talbot, D. E. Low, and The Canadian Streptococcoal Study Group. 1999. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2014a comparative observational study. Clin. Infect. Dis.28:800-807.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/nm1202-800","volume":"8","year":"2002","unstructured":"Kotb, M., A. Norrby-Teglund, A. McGeer, H. El-Sherbini, M. T. Dorak, A. Khurshid, K. Green, J. Peeples, J. Wade, G. Thomson, B. Schwartz, and D. E. Low. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med.8:1398-1404.","journal-title":"Nat. Med."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.4049\/jimmunol.172.3.1719","volume":"172","year":"2004","unstructured":"Llewelyn, M., S. Sriskandan, M. Peakman, D. R. Ambrozak, D. C. Douek, W. W. Kwok, J. Cohen, and D. M. Altmann. 2004. HLA class II polymorphism determines responses to bacterial superantigens. J. Immunol.172:1719-1726.","journal-title":"J. Immunol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev.micro.55.1.77","volume":"55","year":"2001","unstructured":"McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol.55:77-104.","journal-title":"Annu. Rev. Microbiol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.175.1.91","volume":"175","year":"1992","unstructured":"Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. Exp. Med.175:91-98.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.3.994-1003.1995"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/infdis\/166.5.1014","volume":"166","year":"1992","unstructured":"Norgren, M., A. Norrby, and S. E. Holm. 1992. Genetic diversity in T1M1 group A streptococci and its relation to infection. J. Infect. Dis.166:1014-1020.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1086\/514588","volume":"26","year":"1998","unstructured":"Norrby-Teglund, A., H. Basma, J. Andersson, A. McGeer, D. E. Low, and M. Kotb. 1998. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin. Infect. Dis.26:631-638.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1002\/1521-4141(200011)30:11<3247::AID-IMMU3247>3.0.CO;2-D","volume":"30","year":"2000","unstructured":"Norrby-Teglund, A., S. Chatellier, D. E. Low, A. McGeer, K. Green, and M. Kotb. 2000. Host variation in cytokine responses to superantigens determines the severity of invasive group A streptococcal infection. Eur. J. Immunol.30:3247-3255.","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/1521-4141(200209)32:9<2570::AID-IMMU2570>3.0.CO;2-E","volume":"32","year":"2002","unstructured":"Norrby-Teglund, A., G. T. Nepom, and M. Kotb. 2002. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. Eur. J. Immunol.32:2570-2577.","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/infdis\/170.3.585","volume":"170","year":"1994","unstructured":"Norrby-Teglund, A., K. Pauksens, S. E. Holm, and M. Norgren. 1994. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J. Infect. Dis.170:585-591.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/323443","volume":"184","year":"2001","unstructured":"Norrby-Teglund, A., P. Thulin, B. S. Gan, M. Kotb, A. McGeer, J. Andersson, and D. E. Low. 2001. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis.184:853-860.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(03)00099-3","volume":"40","year":"2003","unstructured":"Ohlin, M., and M. Zouali. 2003. The human antibody repertoire to infectious agents: implications for disease pathogenesis. Mol. Immunol.40:1-11.","journal-title":"Mol. Immunol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.9.5011-5017.2000"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.med.51.1.271","volume":"51","year":"2000","unstructured":"Stevens, D. L. 2000. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu. Rev. Med.51:271-288.","journal-title":"Annu. Rev. Med."},{"key":"e_1_3_2_34_2","first-page":"95","volume":"164","year":"1991","unstructured":"Stromberg, A., V. Romanus, and L. G. Burman. 1991. Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J. Infect. Dis.164:95-98.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/003655400459504","volume":"32","year":"2000","unstructured":"Svensson, N., S. Oberg, B. Henriques, S. Holm, G. Kallenius, V. Romanus, and J. Giesecke. 2000. Invasive group A streptococcal infections in Sweden in 1994 and 1995: epidemiology and clinical spectrum. Scand. J. Infect. Dis.32:609-614.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/171.1.74","volume":"171","year":"1995","unstructured":"Watanabe-Ohnishi, R., D. E. Low, A. McGeer, D. L. Stevens, P. M. Schlievert, D. Newton, B. Schwartz, B. Kreiswirth, M. Kotb, and the Ontario Streptococcal Study Project. 1995. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J. Infect. Dis.171:74-84.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.1993.03500030088038","volume":"269","year":"1993","unstructured":"Working Group on Severe Streptococcal Infections. 1993. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA269:390-391.","journal-title":"JAMA"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00271-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00271-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:33Z","timestamp":1627591053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00271-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1128\/CVI.00271-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00271-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"2006-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}